Bipartisan Act Targets Insulin Affordability

The INSULIN Act, a bipartisan Senate bill, seeks to cap monthly insulin costs at $35 for individuals with private insurance. Introduced by Sens. Shaheen, Warnock, Collins, and Kennedy, the legislation also proposes a pilot program in 10 states to offer more affordable insulin to uninsured Americans. This initiative aims to alleviate the significant financial burden of insulin, a drug essential for approximately 8.1 million people in the U.S.

While some states have enacted their own co-pay caps and major insulin manufacturers like Eli Lilly, Sanofi, and Novo Nordisk have taken steps to reduce costs, these measures do not cover all patients. An estimated 57% of Americans with private insurance have self-insured plans, which are not subject to state regulation, leaving them potentially excluded from state-level caps. Furthermore, uninsured individuals or those struggling with manufacturer savings programs may still face access challenges.

Past legislative attempts to cap insulin prices have encountered obstacles. In 2022, a House-passed bill for a $35 monthly cap on private insurance plans did not advance in the Senate. Similarly, an attempt to include such a cap in the Inflation Reduction Act failed due to Republican opposition. Despite these past setbacks, advocates are hopeful that the current bill, with its bipartisan backing, may overcome legislative hurdles and provide much-needed relief.